Farzana Perwad, MD

My research focus is to understand the molecular mechanisms of regulation of phosphorus and vitamin D metabolism in the setting of chronic kidney disease.
Education
2005 - Pediatric Nephrology, University of California San Francisco
MD, 2001 - Pediatrics, Nicklaus Children's Hospital
MBBS, 1996 - Medicine, Kasturba Medical College
Websites
Publications
  1. Genetic Variants Associated with Mineral Metabolism Traits in Chronic Kidney Disease.
  2. Adverse Consequences of Chronic Kidney Disease on Bone Health in Children.
  3. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
  4. Renal Dnase1 expression is regulated by FGF23 but loss of Dnase1 does not alter renal phosphate handling.
  5. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
  6. Chapter 7 The experimental detection of FGF23 responsiveness in target organs.
  7. Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial.
  8. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
  9. Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study.
  10. OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial.
  11. a-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases.
  12. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
  13. Fibroblast growth factor 23 and phosphate homeostasis.
  14. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
  15. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
  16. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
  17. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
  18. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.
  19. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
  20. Fibroblast Growth Factor 23 Expression Is Increased in Multiple Organs in Mice With Folic Acid-Induced Acute Kidney Injury.
  21. Vitamin D and kidney disease.
  22. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
  23. Monogenic Causes of Proteinuria in Children.
  24. Autoimmune hyperphosphatemic tumoral calcinosis.
  25. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
  26. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.
  27. Phosphate Homeostasis and Metabolic Bone Disease.
  28. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues.
  29. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
  30. Chapter 25 Rickets Due to Hereditary Abnormalities of Vitamin D Synthesis or Action.
  31. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23.
  32. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice.
  33. Calcium and Phosphorus.
  34. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.
  35. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency.
  36. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice.